Real-world efficacy of single-agent belantamab mafodotin in relapsed systemic AL amyloidosis.
Jahanzaib KhwajaJoshua BomsztykMaria AttaCeri A BygraveAdam ForbesSenthil DurairajSavio FernandesJames TaylorPamela PatersonGillian BreartonCharles CrawleyOonagh SheehyRachel BrownRichard SoutarMamta GargAndrzej RydzewskiKrzysztof JamroziakShameem MahmoodAshutosh D WechalekarPublished in: British journal of haematology (2024)
Systemic light chain (AL) amyloidosis is a relapsing plasma cell disorder. Therapy is limited, particularly for triple-class refractory disease. We report the use of belantamab mafodotin, a BCMA-directed drug-antibody conjugate, for relapsed AL amyloidosis, including patients traditionally excluded from clinical trials. Thirty-one patients were reviewed, with a median of three prior lines of therapy. The median follow-up was 12 months (95% CI 4-19), and a median of five doses were delivered. The best haematological overall response rate was 71%, and the complete/very good partial response was 58%. Sixty-eight percent had keratopathy and improved in all. Belantamab mafodotin has high efficacy and good tolerability in patients with relapsed AL amyloidosis.
Keyphrases
- multiple myeloma
- end stage renal disease
- acute lymphoblastic leukemia
- acute myeloid leukemia
- ejection fraction
- clinical trial
- chronic kidney disease
- newly diagnosed
- diffuse large b cell lymphoma
- prognostic factors
- peritoneal dialysis
- hodgkin lymphoma
- stem cells
- cell therapy
- randomized controlled trial
- single cell
- emergency department
- rheumatoid arthritis
- open label
- drug delivery
- mesenchymal stem cells
- bone marrow
- drug induced
- adverse drug